Yinli Yang

Tianjin Key Laboratory Of Digestive Cancer
Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Residual disease subtyping predicts survival and guides adjuvant immunotherapy in esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.

Residual disease subtyping predicts survival and guides adjuvant immunotherapy in esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.

Journal: Frontiers in immunology

Published: November 08, 2025

Metabolic and Immunological Implications of MME+CAF-Mediated Hypoxia Signaling in Pancreatic Cancer Progression: Therapeutic Insights and Translational Opportunities.

Metabolic and Immunological Implications of MME+CAF-Mediated Hypoxia Signaling in Pancreatic Cancer Progression: Therapeutic Insights and Translational Opportunities.

Journal: Biological procedures online

Published: June 17, 2024

Anlotinib induced ferroptosis through the p53/xCT/GPX4 pathway in non-small cell lung cancer.

Anlotinib induced ferroptosis through the p53/xCT/GPX4 pathway in non-small cell lung cancer.

Journal: Translational oncology

Published: January 26, 2024

Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.

Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.

Journal: Apoptosis : an international journal on programmed cell death

Published: December 19, 2023

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study.

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study.

Journal: BMC cancer

Published: November 07, 2022

The Combinatorial Effect of Cisplatin and Moxibustion on Tumor Growth Inhibition with Special Reference to Modulation of the Immune Microenvironment in Lewis Lung Cancer Mice.

The Combinatorial Effect of Cisplatin and Moxibustion on Tumor Growth Inhibition with Special Reference to Modulation of the Immune Microenvironment in Lewis Lung Cancer Mice.

Journal: Evidence-based complementary and alternative medicine : eCAM

Published: June 24, 2020

Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.

Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.

Journal: Cancer gene therapy

Published: December 28, 2019

Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.

Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: November 15, 2019

Baicalin reverses radioresistance in nasopharyngeal carcinoma by downregulating autophagy.

Baicalin reverses radioresistance in nasopharyngeal carcinoma by downregulating autophagy.

Journal: Cancer cell international

Published: August 24, 2019

Nociceptin Receptor Is Overexpressed in Non-small Cell Lung Cancer and Predicts Poor Prognosis.

Nociceptin Receptor Is Overexpressed in Non-small Cell Lung Cancer and Predicts Poor Prognosis.

Journal: Frontiers in oncology

Published: February 02, 2019

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors.

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors.

Journal: Thoracic cancer

Published: June 03, 2018

Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.

Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 29, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026